<DOC>
	<DOCNO>NCT01164007</DOCNO>
	<brief_summary>This study assess preliminary antitumor activity safety profile combination Avastin dacarbazine patient unresectable/metastatic melanoma previously treat chemotherapy metastatic disease . Patients receive Avastin 10mg/kg iv every 2 week dacarbazine 800mg/m2 every 4 week . The anticipated time study treatment disease progression .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With Dacarbazine Patients With Unresectable/Metastatic Melanoma .</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; cutaneous malignant melanoma ; clinical evidence metastatic disease and/or unresectable regional lymphatic disease and/or extensive transit recurrent disease ; measurable lesion . prior interferon alfa and/or cytokine therapy metastatic disease ; prior chemotherapy metastatic disease ; brain metastasis ; chronic daily treatment high dose aspirin ( &gt; 325mg/day ) ; coexist malignancy , malignancy diagnose within past 5 year , basal cell cancer cervical cancer situ .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>